AMO ophthalmic viscosurgical device obtains CE Mark of Approval
Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.
Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.
The viscous, low molecular ophthalmic viscosurgical device (OVD) is part of the Healon family and is currently available in Europe, Canada and New Zealand. The Food and Drug Administration (FDA) is presently reviewing the OVD for approval in the US.
Healon EndoCoat can be used as a surgical aid in cataract extraction, corneal transplantation and glaucoma filtration surgery and intraocular lens (IOL) implantation.
The properties of the approved OVD include the 25-gauge cannula delivery system with a guard. The OVD also lubricates and protects the eye during IOL implantation and can be combined with the original Healon OVD, Healon GVD OVD and Healon5 OVD.
Dr Donald Nixon, surgical director of TriMed Eye Center, Ontario, Canada, said: "The OVD plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety."
Customers who presently order shipments of the Vitrax II OVD will be automatically updated to the Healon EndoCoat OVD.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
